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ABSTRACT
INTRODUCTION: Globally, blood transfusions are the cause of transmissible infections in between 10% 
and 15% of all patients. Currently, the testing of donor blood for transmissible infections is utilizing en-
zyme-linked immunosorbent assay ELISA and chemiluminescence method CLIA for screening and detec-
tion of hepatitis C (HCV Ag/Ab). Since February, 2020 all donor samples of blood taken in the 5 centers 
for transfusion hematology in Bulgaria have been tested for markers of transmissible infections, including 
HCV, by nucleic acid testing (NAT).
AIM: We have set the goal to analyze data produced by the implementation of NAT testing of donor blood 
for the period of 4 months (from 10th of February to 16th of June, 2020) regarding HCV infected samples.
MATERIALS AND METHODS: We present our experience of using NAT and data produced by its im-
plementation for testing of donor blood for a period of 4 months, from the time NAT technology was imple-
mented in Bulgaria. 
RESULTS AND DISCUSSION: The performance of the multiplex Procleix Ultrio Elite assay as individu-
al donor nucleic acid test for the detection of HCV is evaluated in a retrospective study. An advantage of the 
method is that it not only allows for timely identification of infected donor blood and saves lives of the recip-
ients but also saves the lives of donors, as treatment of chronic hepatitis C continues to progress and is now 
effective in clearing the virus in more than half of the patients. In terms of safety and security of diagnosis 
and blood products obtained, the method has no alternative. 
CONCLUSION: A recommendation is drafted: to adopt a strategy to increase the quality of healthcare by 
introducing a one-time HCV screening for adults aged 18 and above, for individuals at risk and for pregnant 
women to reduce further the risk of incidental transmission of the hepatitis C virus.
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INTRODUCTION 
Hepatitis C is a serious viral infection caused 
by the hepatitis C virus. It is one of the most serious 
diseases of the liver, with about 170 million people 
chronically infected worldwide and more than 350 
000 dying each year from hepatitis C disease. Like 
hepatitis B, hepatitis C is also often referred to as the 
“silent killer” because people can live with the dis-
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ease for years without knowing they are infected and 
contagious. In Europe, about 15 million people live 
with chronic HCV. A higher percentage of morbid-
ity has been reported in Southern and Eastern Eu-
rope (1). The morbidity rates of acute HCV infections 
for the period 2000-2007 in Bulgaria were 1.52 cases 
per 100000 population, and for the period 2008-2016 
- 1.14 cases per 100000 population (2). In Bulgaria, 
110 000 people are infected with the hepatitis C vi-
rus, with only 0.3-0.5% being treated. 
Initially, hepatitis C is acute, but often becomes 
chronic. Acute hepatitis C either resolves quickly 
without leaving permanent liver damage or becomes 
chronic. Most patients do not notice symptoms dur-
ing the acute phase or the symptoms are often con-
fused and people can live with the virus for many 
years before realizing they are infected. Between 15 
and 45% of those infected with the virus are com-
pletely cleared of it during the acute phase. Chronic 
hepatitis C is a long-term liver infection that develops 
in 55-85% of patients with acute hepatitis C, and can 
lead to serious liver disease, including cirrhosis and 
liver cancer, thus being among the leading causes of 
liver transplants. A total of 20% of those infected de-
velop cirrhosis of the liver. Unlike hepatitis B, there is 
currently no hepatitis C vaccine (1). 
The latest global hepatitis report shows that 
only 20% of people living with HCV are aware of 
their status and that only 8% of those diagnosed with 
HBV and HCV infections received antiviral therapy 
(3). 
A survey published recently showed that exist-
ing testing policies and practices may result in missed 
opportunities to diagnose both HBV and HCV due 
to lack of screening in most countries (4). In Bulgar-
ia, those infected are on average twice less likely to 
be diagnosed as compared to the rest of Europe. The 
problem groups are people who inject drugs, patients 
on hemodialysis, HIV-positive, recipients of contam-
inated blood products, donated blood, or donated or-
gans in the period before 1992, or infected by non-
sterile medical appliances. Approximately 2.3 mil-
lion of those in Europe infected with hepatitis C, are 
also infected with HIV.
Globally, blood transfusions are the cause of 
transmissible infections in between 10% and 15% 
of all patients. In Bulgaria, according to the annu-
al analyses of acute infectious diseases of NCIPD 
for 2015, 2016, and 2017 (https://ncipd.org), patients 
with hepatitis B and hepatitis C due to blood trans-
fusion are on average 12% of all cases for which there 
are established data on the cause of the infection (for 
2015 they are 13%, for 2016 - 14%, for 2017 - 9%). 
These data confirm the global incidence trend and 
prove that, although in many cases life-saving, blood 
transfusion carries risks that must be adequately 
addressed. 
Diagnosis of blood and blood components for 
markers of transmissible infections is performed in 
the centers for transfusion hematology, according to 
the rules of good laboratory practice and in compli-
ance with the requirements of the existing legisla-
tion. Only reagents authorized for use in the Repub-
lic of Bulgaria are used to test the blood taken. Un-
til the end of 2019 each unit of blood taken is test-
ed by mandatory serological tests for HIV-1, HIV-2, 
hepatitis B and hepatitis C. Currently, the diagno-
sis of donor blood for transmissible infections is uti-
lizing enzyme-linked immunosorbent assay ELISA 
and chemiluminescence method CLIA for screen-
ing and detection of hepatitis C (HCV Ag/Ab). Since 
February 2020 all donor samples of blood taken in 
the 5 centers for transfusion hematology in Bulgaria, 
namely National Center for Transfusion Hematolo-
gy (NCRH), Regional Center for Transfusion Hema-
tology Plovdiv (RCTH Plovdiv), Regional Center for 
Transfusion Hematology Stara Zagora (RCTH Sta-
ra Zagora), Regional Center for Transfusion Hema-
tology Pleven (RCTH Pleven) and Regional Center 
for Transfusion Hematology Varna (RCTH Varna), 
have been tested  for the above markers of transmis-
sible infections, including HCV, by nucleic acid test-
ing (NAT). The main advantage of the new technol-
ogy is the shortening of the so-called “window peri-
od” (the time from infection of the donor to the time 
of detection of this infection in the donor blood). 
NAT testing of donor blood for transmissible infec-
tions is without alternative in the increase of the safe-
ty of blood and blood components for transfusion 
and plasma for drug production. At the same time, 
the method leads to significant saving of financial 
resources and ensures that the highest standards for 
donor blood products available currently worldwide 
are met.
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AIM
With this respect we have set the goal to analyze 
data produced by the implementation of NAT test-
ing of donor blood for the period of 4 months (from 
10th of February to 16th of June, 2020) regarding HCV 
infected samples, since NAT technology was imple-
mented in five big centers for transfusion hematol-
ogy in Bulgaria. The performance of the multiplex 
Procleix Ultrio Elite assay as individual donor nucle-
ic acid test for the detection of HCV was evaluated in 
a retrospective study.
MATERIAL AND METHODS 
Blood Donations
A total of 49 390 specimens from blood donors 
were examined in the period from February10th, 
2020 to 16th of June, 2020. The results were provid-
ed by five regional blood transfusion centers in Bul-
garia: National Center for Transfusion Hematology 
(NCRH), Regional Center for Transfusion Hema-
tology Plovdiv (RCTH Plovdiv), Regional Center for 
Transfusion Hematology Stara Zagora (RCTH Sta-
ra Zagora), Regional Center for Transfusion Hema-
tology Pleven (RCTH Pleven) and Regional Center 
for Transfusion Hematology Varna (RCTH Varna). 
Blood donors in Bulgaria meet certain eligibility cri-
teria specified by national guidelines.
Screening Methods 
Testing of blood samples for HCV uses sero-
logic assays that detect human antibodies generated 
as a response to HCV (anti-HCV) or/and HCV anti-
gen. Donor blood samples were tested with enzyme-
linked immunosorbent assay (ELISA) or immuno-
enzymatic assay (EIA) using third and fourth gen-
eration diagnostic kits implemented in the national 
blood transfusion centers and following the guide-
lines of the manufacturers: qualitative enzyme im-
munoassay Monolisa HCV Ag-Ab ULTRA V2 (Bio-
Rad, France) based on the detection of anti-HCV an-
tibodies and capsid antigen in serum or human plas-
ma; Architect Anti-HCV (Abbot, Germany) chemi-
luminescent microparticle immunoassay (CMIA) 
for the qualitative detection of anti-HCV antibod-
ies, and CMIA-based Architect HCV Ag assay (Ab-
bot, Germany) for the quantitative determination of 
HCV core antigen in human serum and plasma. The 
following automated instruments were used for the 
analyses: Architect Anti-HCV Ag core (ABBOTT, 
Wiesbaden, Germany), ETI–Max 3000 (DiaSorin, It-
aly), Evolis System (Bio-Rad Laboratories, France), 
and Elisys Quattro (HUMAN Diagnostics, Germa-
ny). All reactive samples were tested at least twice 
and anti-HCV or HCV Ag positive were tested by al-
ternative NAT using Procleix Panther System (Gri-
fols, Spain), and the qualitative transcription-medi-
ated amplification multiplex Procleix Ultrio Elite as-
say as an individual donor RNA test for the detec-
tion of combined signals for HCV, HBV, and HIV in 
individual donor blood samples was applied. Posi-
tively reactive sampled resulting from the combina-
tory NAT analysis are tested by discriminatory Pro-
cleix Ultrio Elite test for HCV RNA. Sera were diag-
nosed positive with viral hepatitis C by at least one 
of the applied detection methods: antibodies against 
the hepatitis C antigen, hepatitis C antigens or hepa-
titis C RNA, and after a confirmatory testing in the 
national reference laboratory. Donor blood testing 
positive for HCV is discarded and the donor identifi-
cation number is entered into the national informa-
tion system, which automatically excludes these do-
nors from the blood donors’ database. If such indi-
vidual is identified during the screening for eligibil-
ity at any of the regional centers for transfusion he-
matology, he would be automatically eliminated as a 
potential blood donor.
Statistical Analysis
The collected data were organized and analyzed 
using GraphPad Prism 6.0 software. Qualitative data 
were presented as frequency and percentage.
RESULTS AND DISCUSSION
In the period from 10.02.2020 to 16.06.2020 a 
total of 52 of all tested samples were confirmed posi-
tive for anti-HCV by the national reference laborato-
ry, among them one old sample from year 2015. Nine 
samples were positive as determined only by serolog-
ical tests made in 2020 prior to the introduction of 
NAT testing in the national blood transfusion sys-
tem, with a reference conformational test produced 
during the study period. All other 42 blood donor 
samples were analyzed by both serological and mo-
lecular NAT tests with an at least one positive result 
for hepatitis C by either of the test types. Two of the 
donor blood samples reported to the national infor-
mational system were just below the cut-off value 
of the HCV assay and these were listed among the 
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HCV positive and were also excluded from the blood 
bank. One of the blood samples was co-infected with 
syphilis.
Analysis of the results showed that most blood 
donations originated from males – 36 890 (74.6%), 
which is as much as a recent study established for a 
sample of 17 502 739 donations collected for a pe-
riod of six years in Poland (5) and corresponds to a 
roughly estimated male/female blood donor ratio 3:1 
for Bulgaria in the last decade. The shares of infect-
ed blood from male donors vs. female ones, as found 
by this study, is 71% to 29%, respectively, which is 
proportional to the number of male:female blood 
donations.  
In spite of the increasing analytical sensitivity 
of HCV screening tests over the years, the number 
of detected infections in donor blood samples is very 
low – 0.105%. This might be explained by the na-
tionwide implementation of the united information-
al system collecting data from all centers for trans-
fusion hematology in Bulgaria since 2014, which al-
lows to discard blood donors detected with transmis-
sible disease infections earlier and thus to eliminate 
repeating infected blood donors. 
Analysis of the structure of infectious patholo-
gy and morbidity of acute infectious diseases in Bul-
garia in recent years shows that the incidence of vi-
ral hepatitis C per 100 000 is 1.18 (data are for 2017, 
excluding those for influenza and ARI, tuberculosis, 
AIDS and sexually transmitted infections), the total 
number of patients is 84, with a relative share to the 
incidence of acute infectious diseases in Bulgaria of 
0.16% and mortality from HCV infection - 1.19%. Of 
the total number of 3132 cases of viral hepatitis regis-
tered in the same year, viral hepatitis C accounted for 
2.68% and the level of morbidity remains unchanged 
(morbidity 1.18%000) for several consecutive years (6). 
For a period of a year prior to NAT implementation 
in Bulgaria (2016) in the National Reference Labora-
tory for Hepatitis Viruses at the National Centre of 
Infectious and Parasitic Diseases out of 1802 sam-
ples received for differentiation of viral hepatitis or 
for screening of hepatitis markers, 1019 (57%) were 
tested for anti-HCV and 127 (12%) were positive (7). 
It is important to note that these cases are identified 
mainly by the gastroenterological departments and 
general practitioners. The number of cases reported 
for the country per year as compared to results pro-
duced only by NAT analysis of blood donations seem 
to be underestimating the real situation – despite the 
overlapping of a number of cases reported, there still 
exists a slight increase as produced by the results from 
donor blood NAT testing. Blood transfusion centers 
testing may identify either passed infections, chron-
ic infections or early-stage infected individuals, who 
are in the window period in the acute infection, usu-
ally still asymptomatic. Transfusion practice consid-
ers carriers of anti-HCV only potentially infectious 
and blood donations are discarded. Furthermore, the 
analytical serological assays implemented in Bulgar-
ian blood transfusion centers are qualitatively ana-
lyzing the presence of anti-HCV and capsid HCV Ag 
altogether. Only CMIA-based Abbot Architect Anti-
HCV and Architect HCV Ag assays distinguish be-
tween the presence of Anti-HCV and core HCV an-
tigen, respectively, in human serum and plasma and 
thus might distinguish between past and current in-
fections in case of negative Ag results. This could be 
the case for 10 of the blood donors, who were report-
ed negative by NAT testing and positive by the sero-
logical Monolisa HCV Ag-Ab ULTRA V2 testing. By 
the implementation of molecular diagnostic test for 
HCV RNA referred to as NAT, viremic donors might 
be distinguished from donors who have cleared the 
virus. The HCV NAT becomes positive approxi-
mately 1 to 2 weeks after the initial HCV infection 
(8). That is how the NAT test has become the gold 
standard supplemental test for patients who have a 
positive HCV EIA screening test (9,10). NAT can de-
termine whether a patient with a positive HCV anti-
body test has a current (active) or a resolved HCV in-
fection. That could be the case for three of the blood 
donations, which were tested NAT negative, Ag-Ab 
Ultra V2 test assay positive, and HCV core Ag nega-
tive. One could suspect a past infection in these do-
nors. However, an additional testing by other meth-
ods is required to also exclude the presence of capsid 
Ag and the presence of HCV.
Scientists from Varna Regional Blood Trans-
fusion Center approached the NAT analyses from a 
slightly different point of view. A total of 36 NAT-
positive blood samples were established for the stud-
ied period of four months in RCTH Varna, after the 
analysis of 6844 donor samples (0.53 %) and all 36 
samples underwent discriminatory analysis for HB-
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sAg, HCV, and HIV (Table 1). Five of the samples 
tested positive for HCV (13.9%), 1 sample was HIV 
positive (2.8%), and 19 – HBsAg positive (52.8%). 
Discriminatory tests failed to identify one simulta-
neously NAT positive and ELISA HBsAg seropos-
itive blood sample. And serological assays failed to 
identify as positive a total of 17 (47.2%) out of all 36 
NAT-positive samples, which makes almost half of 
them. Discriminatory tests that were carried out af-
terwards confirmed six of those to be HBsAg positive 
and the remaining 11 were unidentified by serologi-
cal or discriminatory tests for the presence of any Ab-
Ag indicative for any of the three types of transmis-
sible infections – HCV, HBV or HIV, and donations 
were also discarded. One possibility is that some of 
those cases could possibly be in the window period, 
which is quite long, e.g. about two months for HCV. 
In case of a very low viral load at the early stage of the 
infection it may fail to be detected by the discrimi-
natory tests. In 2017, when NAT technology was still 
not implemented in the country, 284 cases of unspec-
ified virus hepatitis were established for Bulgaria (in-
cidence 4.00%000), and the incidence in the previous 
seven years varied between 2.7 and 3.9 per 100 000 
population. Patients were tested for serological mark-
ers of HAV, HBV, and HCV, but were not laborato-
ry confirmed for any of the viral types of hepatitis. 
Screening of patients with unspecified acute hepa-
titis indicated 32% presence of anti-HBc in HBsAg-
negative and anti-HBs-negative population (7).  ELI-
SA nonreactive samples theoretically may originate 
from patients who are either in the window phase 
prior to seroconversion or from immunocompro-
mised patients (11). Circumstances associated with a 
false-negative EIA include patients with acute HCV 
infection, persons with major immunosuppression 
(advanced HIV infection or organ transplantation 
recipients), and persons with chronic renal failure 
on long-term hemodialysis, while false-positive tests 
can occur with increased gamma globulin produc-
tion, with autoimmune diseases, and following im-
munizations. The role of NAT in these cases would 
be the detection of the virus within 1-2 weeks of in-
fection, or detection of actual virus rather than im-
mune response. That is where NAT testing may con-
tribute to the clarification of results. Excluding any 
of the donations from the blood storages could pos-
sibly save lives.  
The value of NAT technology should be under-
lined by the fact that it might also be transferred be-
yond the scope of blood transfusions - organ utili-
zation of HBV and/or HCV NAT-negative organs is 
increased over time despite positive antibody status 
(NAT-negative but seropositive), as reported based 
on evaluation of results and utilization information 
for organ donor referrals from 2004 to 2017, out of 
whom 1.8% were HCV antibody-positive and NAT-
negative (12).  The use of NAT for deceased donor 
screening correlated with increased utilization of do-
nor organs. This approach could be of value with re-
gard to donor blood and blood product used for treat-
ment, especially in the developing pandemic situa-
tion of COVID-19. Convalescent plasma products for 
the treatment for COVID-19 patients should be sub-
jected to NAT analysis to eliminate risk from trans-
missible infectious diseases, including HCV. In ad-
dition, with the emergence of direct antiviral agents, 
NAT Discriminatory NAT ELISA Number of Samples
HCV + + + 5
HIV + + + 1
HBsAg
+ + + 12
+ - + 1
+ + - 6
Unspecified + - - 11
Totally 36
Table 1. Results from NAT testing in the Regional Center for Transfusion Hematology - Varna in the period of 10th Feb-
ruary to 16th June, 2020
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there is an increase in data showing the short-term 
outcomes and success of hepatitis C treatment, which 
would reduce HCV spread in the population.
CONCLUSION
We believe that, although the number of sam-
ples analyzed is limited to the blood donations from 
the period since NAT was implemented as a routine 
practice in the blood transfusion centers in Bulgar-
ia, data presented in this study are of value to assess 
the first outcomes of NAT implementation and pos-
sibly reroute the analytical approaches applied in the 
blood transfusion system in Bulgaria and the Nation-
al Reference Laboratory. An advantage of the meth-
od is that it not only allows for timely identification 
of infected donor blood and saves lives of the recipi-
ents but also saves lives of the donors, as treatment of 
chronic hepatitis C continues to progress and is now 
effective in clearing the virus in more than half of the 
patients. In terms of safety and security of diagnosis 
and blood products obtained, the method has no al-
ternative. In conclusion, a recommendation could be 
drafted based on the above results: to adopt a strate-
gy to increase the quality of healthcare by introduc-
ing a one-time HCV screening for adults aged 18 and 
above, for individuals at risk and for pregnant wom-
en to reduce further the risk of incidental transmis-
sion of hepatitis C virus.
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